Development of the PROMOTE model to stratify colorectal cancer risk for prioritization of colonoscopy resource use: a multicenter prospective study

Abstract

Background

Colonoscopy efficacy for colorectal cancer (CRC) prevention is limited by inappropriate or over- prescription. Colonoscopy appropriateness prioritization (CAP) criteria have recently been proposed, but their role in CRC risk stratification remains unclear. The study objective was to derive and validate a predictive model for CRC taking account of CAP criteria, and to assess CRC occurrence in the light of appropriateness of colonoscopies.

Method

In a prospective observational study across 19 Italian centers, including adults undergoing colonoscopy outside CRC screening programs, three cohorts were analyzed for derivation, temporal validation, and geographic validation of the model. CRC risk was estimated by multivariable logistic regression. Model performance was assessed using the area under the receiver operating characteristic (AUROC), and two risk groups were defined: low-risk (<5%) and high-risk (≥5%). Number-needed-to-scope (NNS) was calculated.

Results

The derivation and temporal and geographic validation, cohorts included 2059, 1321, and 1924 patients, respectively, with CRC prevalence 3.6%, 3.9%, and 3%, respectively. CRC was more frequent in appropriate versus inappropriate colonoscopies. The PROMOTE model included: ages 50–59 (odds ratio [OR] 1.89, 95% confidence interval [CI] 0.64–5.59), 60–69 (OR 3.87, 95%CI 1.40–10.71), and ≥70 (OR 5.35, 95%CI 2.04–14.06), versus <50; no colonoscopy in previous 10 years (OR 2.92, 95%CI 1.62–5.25); according to CAP criteria, deferrable (OR 3.44, 95%CI 1.42–8.34) and urgent (OR 16.12, 95%CI 7.15–36.36) versus nonurgent. Discrimination was good (AUROC 0.84, 95%CI 0.79–0.89). NNS was 8–9 in the high-risk group and 67–71 in the low-risk group across validation cohorts.

Conclusion

We developed and validated the PROMOTE model, a simple tool to estimate CRC risk before colonoscopy, to support appropriate referral, optimize prioritization, and improve resource use.

• References

• 1 Sonnenberg A, Amorosi SL, Lacey MJ. et al. Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database. Gastrointest Endosc 2008; 67: 489-496
• 2 Rodríguez de Santiago E, Dinis-Ribeiro M, Pohl H. et al. Reducing the environmental footprint of gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Position Statement. Endoscopy 2022; 54: 797-826
• 3 Early DS, Ben-Menachem T. ASGE Standards of Practice Committee. et al. Appropriate use of GI endoscopy. Gastrointest Endosc 2012; 75: 1127-1131
• 4 Westbury CF. Bayes’ rule for clinicians: An introduction. Front Psychol 2010; 1: 192
• 5 Juillerat P, Peytremann-Bridevaux I, Vader J-P. et al. Appropriateness of colonoscopy in Europe (EPAGE II). Presentation of methodology, general results, and analysis of complications. Endoscopy 2009; 41: 240-246
• 6 Frazzoni L, Marca ML, Radaelli F. et al. Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams. Aliment Pharmacol Ther 2021; 53: 22-32
• 7 Agenzia Nazionale per i Servizi Sanitari Regionali. Manuale RAO [Internet] 2018.. https://www.agenas.gov.it/images/agenas/In%20primo%20piano/RAO/Manuale_RAO_13_gen.pdf
• 8 Gimeno García AZ, González Y, Quintero E. et al. Clinical validation of the European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE) II criteria in an open-access unit: a prospective study. Endoscopy 2012; 44: 32-37
• 9 Argüello L, Pertejo V, Ponce M. et al. The appropriateness of colonoscopies at a teaching hospital: magnitude, associated factors, and comparison of EPAGE and EPAGE-II criteria. Gastrointest Endosc 2012; 75: 138-145
• 10 Hassan C, Antonelli G, Dumonceau J-M. et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020. Endoscopy 2020; 52: 687-700
• 11 Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley; 2000
• 12 Riley RD, Archer L, Snell KIE. et al. Evaluation of clinical prediction models (part 2): how to undertake an external validation study. BMJ 2024; 384: e074820
• 13 Ensor J, Snell K, Martin E. PMCALPLOT: Stata module to produce calibration plot of prediction model performance. Statistical Software Components [Internet] 2020 Jan 4. Accessed August 20, 2025 at: https://www.semanticscholar.org/paper/PMCALPLOT%3A-Stata-module-to-produce-calibration-plot-Ensor-Snell/68b18cbd5b2194796fdbe89fc4b16e511b13ea14
• 14 Collins GS, Reitsma JB, Altman DG. et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015; 162: 55-63
• 15 Moons KGM, Altman DG, Reitsma JB. et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015; 162: W1-73
• 16 Riley RD, Snell KI, Ensor J. et al. Minimum sample size for developing a multivariable prediction model: Part II – binary and time-to-event outcomes. Stat Med 2019; 38: 1276-1296
• 17 Cubiella J, Vega P, Salve M. et al. Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Medicine 2016; 14: 128
• 18 Cubiella J, Digby J, Rodríguez-Alonso L. et al. The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. Int J Cancer 2017; 140: 2201-2211
• 19 Hampton JS, Kenny RPW, Rees CJ. et al. The performance of FIT-based and other risk prediction models for colorectal neoplasia in symptomatic patients: a systematic review. EClinicalMedicine 2023; 64: 102204
• 20 Shapley M, Mansell G, Jordan JL. et al. Positive predictive values of ≥5% in primary care for cancer: systematic review. Br J Gen Pract 2010; 60: e366-377
• 21 Falvey J, Stedman CM, Dunn J. et al. Faecal immunochemical test (FIT) based prioritisation of new patient symptomatic cases referred for colorectal investigation. N Z Med J 2024; 137: 102-110
• 22 Kaminski M, Thomas-Gibson S, Bugajski M. et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy 2017; 49: 378-397
• 23 Rex DK, Schoenfeld PS, Cohen J. et al. Quality indicators for colonoscopy. Gastrointest Endosc 2015; 81: 31-53
• 24 Fuccio L, Collatuzzo G, Frazzoni L. et al. Impact of colonoscopy on working productivity: a prospective multicenter observational study. Gastrointest Endosc 2022; 95: 550-561.e8
• 25 Ricciardiello L, Ferrari C, Cameletti M. et al. Impact of SARS-CoV-2 pandemic on colorectal cancer screening delay: effect on stage shift and increased mortality. Clin Gastroenterol Hepatol 2021; 19: 1410-1417.e9
• 26 Eskeland SL, Dalén E, Sponheim J. et al. European panel on the appropriateness of gastrointestinal endoscopy II guidelines help in selecting and prioritizing patients referred to colonoscopy – a quality control study. Scand J Gastroenterol 2014; 49: 492-500
• 27 Carrión S, Marín I, Lorenzo-Zúñiga V. et al. Appropriateness of colonoscopy indications according to the new EPAGE II criteria. Article in Spanish. Gastroenterol Hepatol 2010; 33: 484-489
• 28 Bretthauer M, Løberg M, Wieszczy P. et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. N Engl J Med 2022; 387: 1547-1556